Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Amanda Fredericks"'
Publikováno v:
Clinical journal of oncology nursing. 25(2)
Background Many patients with locally advanced or metastatic urothelial carcinoma (mUC) need additional treatment options beyond PD-1 or PD-L1 inhibitors and platinum-based chemotherapies. Enfortumab vedotin-ejfv (EV) is an antibody-drug conjugate di
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b55923a126ce6f40d9fd941be055d660
https://pubmed.ncbi.nlm.nih.gov/33739346
https://pubmed.ncbi.nlm.nih.gov/33739346
Autor:
Brandon Bernard, Jeffrey G. Supko, Christopher Sweeney, Philip W. Kantoff, Atish D. Choudhury, Lauren C. Harshman, Matthew S. Farina, Kathryn P. Gray, Mary-Ellen Taplin, Amanda Fredericks Pace, Katherine Zukotynski, Mark Pomerantz
Publikováno v:
The Prostate. 78:1053-1062
Background Cabozantinib can enhance the effect of abiraterone in preclinical prostate cancer models. This study aimed to define the recommended phase 2 dose (RP2D) and preliminary efficacy of abiraterone + cabozantinib in mCRPC. Methods Patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::899c1cd4d321c5401f100b43d1e8674e
https://doi.org/10.1002/pros.23662
https://doi.org/10.1002/pros.23662
Autor:
Atish Dipankar Choudhury, Wanling Xie, Edmund Folefac, Daniel Lee, Mamta Parikh, David Johnson Einstein, Elizabeth R Kessler, Tina M. Mayer, Rana R. McKay, Amanda Fredericks Pace, Bose Kochupurakkal, Kent William Mouw, Eliezer Mendel Van Allen, Charles Kunos, Alan D. D'Andrea, Mary-Ellen Taplin, Geoffrey Shapiro
Publikováno v:
Journal of Clinical Oncology. 39:5034-5034
5034 Background: Alterations in DNA damage repair (DDR) genes are common in metastatic castration-resistant prostate cancer (mCRPC), and are implicated in responses to carboplatin [carbo], PARP inhibitors and immunotherapeutics. Inhibitors of the ATR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1d9a06960fecbe7621df6f47b50825f6
https://doi.org/10.1200/jco.2021.39.15_suppl.5034
https://doi.org/10.1200/jco.2021.39.15_suppl.5034
Autor:
Mark Pomerantz, Rupal S. Bhatt, Lucia Kwak, Alexander Cheung, Heather A. Jacene, Bradley Alexander McGregor, Kerry L. Kilbridge, Eliezer M. Van Allen, Xiao X. Wei, Glenn J. Bubley, Mary-Ellen Taplin, Abhishek Tripathi, Atish D. Choudhury, Christopher Sweeney, Lawrence Fong, Lauren C. Harshman, Amanda Fredericks Pace
Publikováno v:
Journal of Clinical Oncology. 39:98-98
98 Background: Treatment (tx) options for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) to bone are limited. Radium-223 (R223) has demonstrated overall survival (OS) benefit, but objective clinical responses to R223 or t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::445ebd9a253b1c52479fa06b278d0a17
https://doi.org/10.1200/jco.2021.39.6_suppl.98
https://doi.org/10.1200/jco.2021.39.6_suppl.98
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Mark Pomerantz, Laura Polacek, Susanna Jacobus, Atish D. Choudhury, Christopher Sweeney, Meghara K. Walsh, Judith Prisby, Rana R. McKay, Toni K. Choueiri, Lillian Werner, Amanda Fredericks Pace, Mary-Ellen Taplin, Hannah Mills
Publikováno v:
Journal of Medical Internet Research
Background: The pace of drug discovery and approvals has led to expanding treatments for cancer patients. Although extensive research exists regarding barriers to enrollment in oncology clinical trials, there are limited studies evaluating processes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d65c2d93971d7c79fc25b7a9c7f4cc2e
https://doi.org/10.2196/12044
https://doi.org/10.2196/12044
Autor:
Laura Polacek, Meghara K. Walsh, Susanna Jacobus, Lillian Werner, Amanda Fredericks Pace, Judith Prisby, Christopher Sweeney, Mary-Ellen Taplin, Toni K. Choueiri, Hannah Mills, Mark Pomerantz, Rana R. McKay, Atish D. Choudhury
Publikováno v:
Journal of Clinical Oncology. 35:266-266
266 Background: Most advances in the diagnosis and treatment (Tx) of patients (pts) with genitourinary (GU) cancers are the result of pt involvement in CTs. There is a clear need to identify ways to improve CT processes for pts and research teams (RT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::58f8e0b8ed320fed9624263e744a8e6c
https://doi.org/10.1200/jco.2017.35.6_suppl.266
https://doi.org/10.1200/jco.2017.35.6_suppl.266
Autor:
Lauren C. Harshman, Mark Pomerantz, Amanda Fredericks Pace, Mary-Ellen Taplin, Christopher Sweeney, Jeffrey G. Supko, Katherine Zukotynski, Aymen Elfiky, Kathryn P. Gray, Brandon Bernard, Philip W. Kantoff, Kathryn Dumas
Publikováno v:
Journal of Clinical Oncology. 33:5037-5037
5037 Background: A and C (multi-tyrosine kinase inhibitor including MET and VEGFRs) have complementary mechanisms of action and activity in CRPC. In vivo work with LAPC4-CR (castration and A resistant cell line) has shown the combination has enhanced
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::21588b56f26d73cec4adf01445ba17a8
https://doi.org/10.1200/jco.2015.33.15_suppl.5037
https://doi.org/10.1200/jco.2015.33.15_suppl.5037
Autor:
Philip W. Kantoff, Aymen Elfiky, Amanda Fredericks, Kathryn P. Gray, Mary-Ellen Taplin, Christopher Sweeney, Lauren C. Harshman, Kathryn Dumas, Toni K. Choueiri, Mark Pomerantz
Publikováno v:
Journal of Clinical Oncology. 32:5027-5027
5027^ Background: Abi (CYP17A1 and lyase inhibitor) and cabo (multi-tyrosine kinase inhibitor including MET and VEGFRs) have complementary mechanisms of action. Both have single agent activity in C...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e5fe780b139a16c9e3b7528a3722db04
https://doi.org/10.1200/jco.2014.32.15_suppl.5027
https://doi.org/10.1200/jco.2014.32.15_suppl.5027